In contrast, Dex inhibited radiation-induced increase in pro-oxidant levels and enhanced the clonogenic survival in normal hematopoietic stem and progenitor cells

In contrast, Dex inhibited radiation-induced increase in pro-oxidant levels and enhanced the clonogenic survival in normal hematopoietic stem and progenitor cells. glycol (PEG)-conjugated copper, zinc-superoxide dismutase, and PEG-catalase significantly guarded Mitomycin C myeloma cells from Dex-induced clonogenic death. Overall, these results demonstrate that Dex in combination with radiotherapy enhances the killing of myeloma cells while protecting normal bone marrow hematopoiesis through a mechanism that involves selective raises in oxidative stress. == Intro == Radiation therapy is definitely a powerful treatment modality for multiple myeloma (MM) [1,2]. External beam irradiation is frequently utilized Mitomycin C for palliation of bone pain and eradication of solitary plasmacytomas [3,4]. In myeloma individuals who present diffused bone disease, systemic radiotherapy with providers such as bone-seeking radionuclides and radioimmunotherapy [5, 6] or Mitomycin C option techniques like intensity-modulated radiation therapy and helical tomography [7,8] have been explored. Bone-seeking radionuclide therapy with radioactive samarium conjugated to a tetraphosphonate chelator (153-Sm-EDTMP) has been used in myeloablative medical protocols for MM [9-12]. The combination of radiotherapy with novel chemotherapeutic providers such as thalidomide [13] and bortezomib [14,15] has shown good medical outcomes with reduced radiotoxicity to normal tissues. Screening of antimyeloma medicines in combination with bone-seeking radiotherapy is definitely worthy of investigation because MM is an inherently radiosensitive malignancy. Furthermore, such radiation-based combination regimens may require less aggressive interventions (nonmyeloablative) that may be offered to seniors individuals who comprise the present and future majority of MM individuals [16,17]. Dexamethasone (Dex) is definitely FST a synthetic steroidal glucocorticoid that is widely used in the treatment of MM in solitary [18] and combination chemotherapy regimens [19]. The antimyeloma effect of Dex has been partly elucidated [20,21]. The major impediments to the effective use of Dex in myeloma remedy are acquired Dex resistance due to prolonged utilization and/or disease progression [22,23] and toxicities with combination chemotherapy providers without an improved survival benefit [24]. Dex is also an anti-inflammatory drug that inhibits the activation of the redox-regulated prosurvival transcription factors nuclear element B (NF-B) and activator protein 1 (AP-1) that govern cellular radiosensitivity [25]. Dex offers been shown to inhibit IL-6 manifestation [26], and an NF-B- and c-Jun-mediated IL-6 manifestation has been reported in myeloma cells [27]. IL-6 has been established like a prosurvival and proproliferative Mitomycin C cytokine in MM [28] that may be controlled from the redox status of the tumor cells [29]. On the basis of the direct myeloma cytotoxicity and anti-inflammatory nature of Dex, we hypothesized that Dex-induced redox perturbations could potentially augment radiation-induced myeloma cell death by enhancing oxidative stress. Myeloma cells may exist inside a pro-oxidant state as evidenced by improved markers of lipid peroxidation and lower levels of antioxidant enzymes in individuals with MM, relative to healthy regulates [3032]. Dex has been suggested to induce oxidative cell death in T-cell lymphoma [3335]; however, a definite part for Dex in inducing oxidative stress in MM has not been founded [36,37]. In normal cells, Dex offers been shown to inhibit reactive oxygen species (ROS) generation in mononuclear cells and polymorphonuclear leukocytes [38], protect hepatocytes against cadmium toxicity by increasing levels of metallothionein and cellular thiols [39] and reduce oxidative DNA fragmentation induced by hydrogen peroxide (H2O2) in the nose mucosa [40]. It is well established that ionizing radiation (IR) actuates the production of free radicals (such as superoxide [O-2] and H2O2) that induce oxidative stress-induced cell death [25]. Because myeloma cells seem to demonstrate improved levels of endogenous metabolic oxidative stress, relative to normal cells, and radiation is definitely a potent.